Gilead Sciences expands access to AIDS drugs
July 12 (The Hindu) Biopharma company Gilead Sciences on Tuesday announced expansion of its global access programme to provide accelerated access to drugs for treatment of HIV/AIDS.
At a press conference to mark the announcement, Gilead’s Executive Vice-President, Corporate & Medical Affairs, Gregg H. Alton, said the expansion plan included new licensing terms with four India-based manufacturers — Hetero Drugs, Matrix Laboratories, Ranbaxy Laboratories and Strides Arcolab — for three drugs currently in the late-stage clinical development. The drugs were expected to be out in the market before the end of 2012.
In a presentation, he traced the drug discovery and access process over the years and specifically recalled how from a multi-drug daily consumption routine, it was now close to being a single tablet regimen for HIV treatment. Gilead was over 1.1 million patients in developing countries got Gilead HIV medication produced by Indian companies. Mr. Alton said about 1.6 million patients consumed either generic or branded Giliead HIV medicines, representing nearly one-fourth of the 6.6 million patients getting HIV therapy.
Among others present were: Ron Somers, President, U.S.-India Business Council, Bhavesh Shah, Vice-President, International Marketing, Hetero Drugs, Arun K. Purohit, Vice-President & Head, Global Therapy Management, Ranbaxy, and Hari Babu of Matrix Laboratories.
News Gathered by India News
Become a Hosting Provider
Get Domain Reseller Account Free .in domain Rs 115 Reseller Hosting in just Rs 999